Search results
Pfizer hemophilia gene therapy arrives in US to uncertain future
BioPharma Dive via Yahoo Finance· 7 days ago“The handwriting is on the wall regarding Roctavian,” Piper Sandler analyst Christopher Raymond...
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know
Zacks via Yahoo Finance· 11 hours agoTaysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a...
Think You Need A Good Stock? Look At This Taysha Gene Therapies Inc
Stocks Register· 2 days agoLong term indicators on average place the stock in the category of 100% Buy. Looking further, we note the current price level is -7.56% off its SMA20 and ...
Intra-Cellular Therapies (NASDAQ:ITCI) Rating Reiterated by Cantor Fitzgerald
ETF DAILY NEWS· 7 days agoCantor Fitzgerald’s price objective indicates a potential upside of 66.37% from the stock’s previous close. Several other equities analysts have also weighed in on the company ...
These Are The 5 Best Stocks To Buy And Watch Now
Investor's Business Daily· 6 hours agoBuying a stock is easy, but buying the right stock without a time-tested strategy is incredibly hard. So which are the best stocks to buy now or put on a...
Carvana upgraded, Block downgraded: Wall Street's top analyst calls
The Fly via Yahoo Finance· 12 hours agoExane BNP Paribas initiated coverage of IBM (IBM) with an Underperform rating and $145 price target....
US Physical Therapy expands with new acquisitions By Investing.com
Investing.com· 1 day agoU.S. Physical Therapy, Inc. (NYSE: USPH), a prominent national operator of outpatient physical ...
Don't Be a Victim: 21 Cheap Ways to Protect Yourself From Thieves
Cheapism via AOL· 1 day agoAfrica Studio/shutterstock Find Clever Hiding Places for Valuables Above all else, don't stash...
Taysha Gene Therapies Inc (TSHA) receives an Overweight rating from Piper Sandler – Knox Daily
Knox Daily· 3 days agoB now holds 16,466,667 shares, worth roughly $39.36 million. Piper Sandler initiated its Taysha Gene Therapies Inc [TSHA] rating to an Overweight in a research note published ...
Bobby Gaspar
Time Magazine· 13 hours agoDr. Bobby Gaspar, CEO of Orchard Therapeutics, has the dubious honor of making the most expensive medicine—at $4.5 million per dose—currently on the...
